Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban 10 mg or 20 mg versus aspirin for extended prevention of recurrent venous thromboembolism
2013-000619-26Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban and aspirin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (3 arms), sponsored by Bayer. Primary endpoint: Primary efficacy endpoint. Started Dec 2013; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2013-000619-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000619-26.